Laura Frain1, David Swanson2, Kelly Cho3, David Gagnon4, Kun Ping Lu5, Rebecca A Betensky6, Jane Driver7. 1. Division of Aging, Brigham and Women's Hospital, Boston, MA, USA. 2. Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway. 3. Division of Aging, Brigham and Women's Hospital, Boston, MA, USA; Massachusetts Veterans Epidemiology and Resource Information Center (MAVERIC), VA Boston Healthcare System (VABHS), Jamaica Plain, MA, USA. 4. Massachusetts Veterans Epidemiology and Resource Information Center (MAVERIC), VA Boston Healthcare System (VABHS), Jamaica Plain, MA, USA; Boston University School of Public Health, Boston, MA, USA. 5. Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA. 6. Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 7. Division of Aging, Brigham and Women's Hospital, Boston, MA, USA; Massachusetts Veterans Epidemiology and Resource Information Center (MAVERIC), VA Boston Healthcare System (VABHS), Jamaica Plain, MA, USA; Geriatric Research Education and Clinical Center, VABHS, Jamaica Plain, MA, USA. Electronic address: jane.driver@va.gov.
Abstract
INTRODUCTION: To examine the risk of Alzheimer's disease (AD) among cancer survivors in a national database. METHODS: Retrospective cohort of 3,499,378 mostly male US veterans aged ≥65 years were followed between 1996 and 2011. We used Cox models to estimate risk of AD and alternative outcomes (non-AD dementia, osteoarthritis, stroke, and macular degeneration) in veterans with and without a history of cancer. RESULTS: Survivors of a wide variety of cancers had modestly lower AD risk, but increased risk of the alternative outcomes. Survivors of screened cancers, including prostate cancer, had a slightly increased AD risk. Cancer treatment was independently associated with decreased AD risk; those who received chemotherapy had a lower risk than those who did not. DISCUSSION: Survivors of some cancers have a lower risk of AD but not other age-related conditions, arguing that lower AD diagnosis is not simply due to bias. Cancer treatment may be associated with decreased risk of AD. Published by Elsevier Inc.
INTRODUCTION: To examine the risk of Alzheimer's disease (AD) among cancer survivors in a national database. METHODS: Retrospective cohort of 3,499,378 mostly male US veterans aged ≥65 years were followed between 1996 and 2011. We used Cox models to estimate risk of AD and alternative outcomes (non-AD dementia, osteoarthritis, stroke, and macular degeneration) in veterans with and without a history of cancer. RESULTS: Survivors of a wide variety of cancers had modestly lower AD risk, but increased risk of the alternative outcomes. Survivors of screened cancers, including prostate cancer, had a slightly increased AD risk. Cancer treatment was independently associated with decreased AD risk; those who received chemotherapy had a lower risk than those who did not. DISCUSSION: Survivors of some cancers have a lower risk of AD but not other age-related conditions, arguing that lower AD diagnosis is not simply due to bias. Cancer treatment may be associated with decreased risk of AD. Published by Elsevier Inc.
Authors: Bin Zhang; Arpita Maiti; Sharon Shively; Fara Lakhani; Gaye McDonald-Jones; Jennifer Bruce; Edward B Lee; Sharon X Xie; Sonali Joyce; Chi Li; Philip M Toleikis; Virginia M-Y Lee; John Q Trojanowski Journal: Proc Natl Acad Sci U S A Date: 2004-12-22 Impact factor: 11.205
Authors: Andrew J Saykin; Li Shen; Xiaohui Yao; Sungeun Kim; Kwangsik Nho; Shannon L Risacher; Vijay K Ramanan; Tatiana M Foroud; Kelley M Faber; Nadeem Sarwar; Leanne M Munsie; Xiaolan Hu; Holly D Soares; Steven G Potkin; Paul M Thompson; John S K Kauwe; Rima Kaddurah-Daouk; Robert C Green; Arthur W Toga; Michael W Weiner Journal: Alzheimers Dement Date: 2015-07 Impact factor: 21.566
Authors: Igor Akushevich; Julia Kravchenko; Svetlana Ukraintseva; Konstantin Arbeev; Alexander Kulminski; Anatoliy I Yashin Journal: Exp Gerontol Date: 2013-09-21 Impact factor: 4.032
Authors: Wildon R Farwell; Richard E Scranton; Elizabeth V Lawler; Robert A Lew; Mary T Brophy; Louis D Fiore; J Michael Gaziano Journal: J Natl Cancer Inst Date: 2008-01-08 Impact factor: 13.506
Authors: Ferrán Catalá-López; Marta Suárez-Pinilla; Paula Suárez-Pinilla; Jose María Valderas; Manuel Gómez-Beneyto; Salvador Martinez; Vicent Balanzá-Martínez; Joan Climent; Alfonso Valencia; John McGrath; Benedicto Crespo-Facorro; Jose Sanchez-Moreno; Eduard Vieta; Rafael Tabarés-Seisdedos Journal: Psychother Psychosom Date: 2014-01-22 Impact factor: 17.659
Authors: Heidi A Hanson; Kevin P Horn; Kelli M Rasmussen; John M Hoffman; Ken R Smith Journal: J Gerontol B Psychol Sci Soc Sci Date: 2017-10-01 Impact factor: 4.077
Authors: Jane A Driver; Alexa Beiser; Rhoda Au; Bernard E Kreger; Greta Lee Splansky; Tobias Kurth; Douglas P Kiel; Kun Ping Lu; Sudha Seshadri; Phillip A Wolf Journal: BMJ Date: 2012-03-12
Authors: Erin L Abner; Peter T Nelson; Gregory A Jicha; Gregory E Cooper; David W Fardo; Frederick A Schmitt; Richard J Kryscio Journal: J Alzheimers Dis Date: 2019 Impact factor: 4.472
Authors: Anne G Ording; Erzsébet Horváth-Puhó; Katalin Veres; M Maria Glymour; Mikael Rørth; Henrik T Sørensen; Victor W Henderson Journal: Alzheimers Dement Date: 2020-05-20 Impact factor: 21.566
Authors: Michele Salemi; Maria Paola Mogavero; Giuseppe Lanza; Laura M Mongioì; Aldo E Calogero; Raffaele Ferri Journal: Cells Date: 2022-06-15 Impact factor: 7.666